Regencell Bioscience Holdings Limited

NasdaqCM RGC

Regencell Bioscience Holdings Limited Market Capitalization on January 14, 2025: USD 63.24 M

Regencell Bioscience Holdings Limited Market Capitalization is USD 63.24 M on January 14, 2025, a -51.59% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Regencell Bioscience Holdings Limited 52-week high Market Capitalization is USD 194.67 M on July 23, 2024, which is 207.82% above the current Market Capitalization.
Regencell Bioscience Holdings Limited 52-week low Market Capitalization is USD 41.64 M on July 16, 2024, which is -34.16% below the current Market Capitalization.
Regencell Bioscience Holdings Limited average Market Capitalization for the last 52 weeks is USD 79.31 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

NasdaqCM: RGC

Regencell Bioscience Holdings Limited

CEO	Mr. Yat-Gai Au
IPO Date	July 16, 2021
Location	Hong Kong
Headquarters	First Commercial Building
Employees	12
Sector	Health Care
Industries Biotechnology Pharmaceuticals Research & Consulting

Description

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Key trends

Past 5 years